[go: up one dir, main page]

MX2013003816A - Novel combinations. - Google Patents

Novel combinations.

Info

Publication number
MX2013003816A
MX2013003816A MX2013003816A MX2013003816A MX2013003816A MX 2013003816 A MX2013003816 A MX 2013003816A MX 2013003816 A MX2013003816 A MX 2013003816A MX 2013003816 A MX2013003816 A MX 2013003816A MX 2013003816 A MX2013003816 A MX 2013003816A
Authority
MX
Mexico
Prior art keywords
agonist
inhibitor
novel combinations
kinase inhibitor
product
Prior art date
Application number
MX2013003816A
Other languages
Spanish (es)
Inventor
Svetlana Ivanova
Peter Robert Hansen
Frank Burkamp
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2013003816A publication Critical patent/MX2013003816A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a pharmaceutical product comprising, in combination, (1) a named glucocorticosteroid receptor agonist and (2) a β2 adrenoreceptor agonist, a dual β2 adrenoreceptor agonist/M3 receptor antagonist, a muscarinic antagonist, a p38 kinase inhibitor, a neutrophil elastase inhibitor, a phosphodiesterase PDE4 inhibitor, an IKK2 kinase inhibitor or a non-steroidal glucocorticoid receptor agonist, and the use of said product in treating respiratory diseases.
MX2013003816A 2010-10-07 2011-10-05 Novel combinations. MX2013003816A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1016912.6A GB201016912D0 (en) 2010-10-07 2010-10-07 Novel combination
PCT/GB2011/051898 WO2012046050A1 (en) 2010-10-07 2011-10-05 Novel combinations

Publications (1)

Publication Number Publication Date
MX2013003816A true MX2013003816A (en) 2013-05-01

Family

ID=43304217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003816A MX2013003816A (en) 2010-10-07 2011-10-05 Novel combinations.

Country Status (14)

Country Link
EP (1) EP2624838A1 (en)
JP (1) JP2013538867A (en)
KR (1) KR20130126595A (en)
CN (1) CN103249418A (en)
AU (1) AU2011311310A1 (en)
BR (1) BR112013008362A2 (en)
CA (1) CA2813684A1 (en)
GB (1) GB201016912D0 (en)
IL (1) IL225312A0 (en)
IN (1) IN2013MN00567A (en)
MX (1) MX2013003816A (en)
RU (1) RU2013115103A (en)
SG (1) SG188575A1 (en)
WO (1) WO2012046050A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150027922A (en) * 2013-09-04 2015-03-13 주식회사 대웅제약 Novel antifungal pyridinylhydrazide derivatives
KR101657678B1 (en) * 2013-11-05 2016-09-20 주식회사 대웅제약 Novel compound, method for preparation thereof, and antifungal composition comprising the same
CN108349999A (en) * 2015-11-16 2018-07-31 埃斯蒂文博士实验室股份有限公司 Oxadiazaspiro compounds for the treatment of drug abuse and addiction
CN109195975B (en) * 2016-09-30 2022-01-04 四川海思科制药有限公司 Diazaspiro [5.5] undecane derivative and application thereof
CN117024499A (en) * 2023-07-17 2023-11-10 陕西汉江药业集团股份有限公司 Preparation method of steroid compound with methylene hydroxyl introduced at 2-position

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
SE0102616D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
CA2458534C (en) 2001-09-14 2011-11-01 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
BR0315234A (en) 2002-10-11 2005-08-23 Pfizer Indole derivatives as beta-2 agonists
DK1556342T3 (en) 2002-10-28 2008-07-21 Glaxo Group Ltd Phenethanolamine derivative for the treatment of respiratory diseases
SE0300091D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
PE20040950A1 (en) 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
WO2004106333A1 (en) 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024453A1 (en) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting bronchodilators for the treatment of respiratory diseases
JP2008501705A (en) 2004-06-03 2008-01-24 セラヴァンス， インコーポレーテッド Diamine β2 adrenergic receptor agonist
US20060002967A1 (en) 2004-07-01 2006-01-05 Smestad Thomas L Resorbable implant with lubricious coating
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0425057D0 (en) 2004-11-12 2004-12-15 Pfizer Ltd L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
US20060114254A1 (en) 2004-11-26 2006-06-01 Tim Day Volume rendering apparatus and method
WO2006066907A1 (en) 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
ES2265276B1 (en) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
GB0512246D0 (en) 2005-06-15 2005-07-27 Glaxo Group Ltd Novel pharmaceutical
EA016203B1 (en) 2006-03-20 2012-03-30 Пфайзер Лимитед Amine derivatives
ES2296516B1 (en) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
DE502007006951D1 (en) 2006-08-07 2011-05-26 Boehringer Ingelheim Pharma MEDICINAL COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
PE20081358A1 (en) 2006-08-22 2008-10-31 Boehringer Ingelheim Int PHARMACOLOGICAL COMBINATIONS FOR THE TREATMENT OF DISEASES OF THE AIRWAY
JP2010505810A (en) 2006-10-04 2010-02-25 ファイザー・リミテッド Sulfonamide derivatives as adrenergic and muscarinic antagonists
ES2302447B1 (en) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
SA08280783B1 (en) 2007-01-11 2011-04-24 استرازينيكا ايه بي Pyridopyrimidine Derivatives as PDE4 Inhibitors
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
ES2306595B1 (en) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 .
WO2008106016A2 (en) 2007-02-27 2008-09-04 Metrosol, Inc. Prism spectrometer with moveable detector element and with collimated input light
GB0703999D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
BRPI0813244B8 (en) 2007-06-27 2021-05-25 Astrazeneca Ab compounds derived from pyrazinone, compositions comprising said compounds, use of the compounds in the treatment of lung diseases and intermediate compound
MX2010003698A (en) * 2007-10-04 2010-04-21 Astrazeneca Ab Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity.
EA018711B1 (en) 2008-02-06 2013-10-30 Астразенека Аб Diazaspiro[5.5]undecane derivatives as muscarinic receptor antagonists and beta-adrenoceptor agonists for use in the treatment of pulmonary disorders
KR20110010725A (en) 2008-05-13 2011-02-07 아스트라제네카 아베 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST
EP2300464A1 (en) 2008-05-13 2011-03-30 AstraZeneca AB Quinuclidine derivatives as muscarinic m3 receptor antagonists
UY32520A (en) 2009-04-03 2010-10-29 Astrazeneca Ab COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802

Also Published As

Publication number Publication date
EP2624838A1 (en) 2013-08-14
WO2012046050A1 (en) 2012-04-12
IL225312A0 (en) 2013-06-27
GB201016912D0 (en) 2010-11-24
AU2011311310A1 (en) 2013-04-11
IN2013MN00567A (en) 2015-10-09
CN103249418A (en) 2013-08-14
SG188575A1 (en) 2013-04-30
BR112013008362A2 (en) 2016-06-14
RU2013115103A (en) 2014-11-20
JP2013538867A (en) 2013-10-17
CA2813684A1 (en) 2012-04-12
KR20130126595A (en) 2013-11-20

Similar Documents

Publication Publication Date Title
UY32521A (en) COMBINATION TO USE IN THE TREATMENT OF RESPIRATORY DISEASES
ATE469895T1 (en) CGRP RECEPTOR ANTAGONISTS
CR10309A (en) "COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1"
BR112013008140A2 (en) "imidazotriazinone compounds".
MX2009007944A (en) Compounds and compositions as kinase inhibitors.
CL2009000171A1 (en) Compounds derived from 1-oxa-3-azaspiro, antagonists of the neuropeptide y5 receptor y (npy); pharmaceutical composition comprising said compound; and use for the treatment of eating disorders, drinking disorders, obesity, and depression.
NZ592544A (en) Isonicotinamide orexin receptor antagonists
WO2008127226A3 (en) P13 kinase antagonists
CL2007002017A1 (en) COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE.
UA95768C2 (en) MUSCARIN ANTEGONYL ACETILON ANTAGONISTS
MY154898A (en) P70 s6 kinase inhibitors
CL2008001705A1 (en) Compounds derived from nitrogen heterocycles; and use of the compound for the treatment of histamine h3 receptor related diseases or disorders.
MX2009006339A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity.
ZA200800431B (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
ZA200606056B (en) Selected CGRP antagonists, methods for the production thereof and their use as medicaments
MX2009008363A (en) Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist.
WO2010116282A8 (en) 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
IL189497A0 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
MX2013003816A (en) Novel combinations.
WO2006048248A3 (en) Novel anthranilamide pyridinureas as vegf receptor kinase imhibitors
CL2008000091A1 (en) COMPOUNDS DERIVED FROM PIRIDINA, INHIBITORS OF THE P2Y12 RECEIVER; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE PLAQUETARY AGREGATION DISORDER.
WO2009156680A3 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
MX2010012019A (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist.
EP2323656A4 (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist